Life Science News

  • The Gummy Project'S Watermelon Sharks and Peachy Bees are now available for pre-sale purchase at www.shopgummies.com
  • Shipping and fulfilment of online orders will commence on July 11, 2022

The Gummy Project (CSE: GUMY) (FSE: 0OS2) (OTCQB: POTVF) ("GUMY" or the "Company") is pleased to announce the official launch of its new e-commerce site at www.shopgummies.com.

"The launch of our e-commerce site is a major milestone, making our product available across Canada for the first time," said Anthony Gindin, Chief Marketing Officer at GUMY. "This really marks our official launch into the Canadian market with e-commerce being a major component in our overall sales channel strategy. The site provides a vehicle for continued growth as well as a platform to share our story and fulfil our mandate to support endangered keystone species."

Both the Watermelon Sharks and Peachy Bees are now available for sale at www.shopgummies.com. Each bag contains 22 gummies with only two grams of sugar while being plant based, gluten free and non-GMO.

Shipping and fulfilment of online orders will commence on July 11, 2022.

"The initial feedback received on both the flavor formulations and the packaging has been tremendous and we are extremely excited that our gummies will now be available to consumers nationwide in Canada through our e-commerce platform," said Charlie Lamb, President and CEO of GUMY. "Our development team did a wonderful job building a website that not only looks fantastic but is also very user friendly."

ABOUT The Gummy Project

We are a growing community of individuals and organizations who believe small contributions can add up to something big. We sell low sugar, plant based gummy products while raising money (and awareness) to support endangered keystone species. We are the only "better for you" candy company that is built to support our planet's most precious species and ecosystems, while educating our future generations on the steps we must take today, to ensure a viable tomorrow.

Charlie Lamb, President & CEO, Director
Telephone: 1(236) 317-2812 - Toll free (877) 806-2633
E-mail: investors@shopgummies.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID-19, including the impact of COVID-19 on the Company's business, financial condition, and results of operations. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129624

News Provided by Newsfile via QuoteMedia

GUMY:CC
The Gummy Project Announces Launch of New Investor Relations Website

The Gummy Project Announces Launch of New Investor Relations Website

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company")  is pleased to announce the launch of its new investor relations website at https:shopgummies.compagesinvestors.

The investor relations website features excellent functionality and streamlined access to essential investor information, including recent company press releases, sector information and more.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Announces That Its Gummies Land on North America's Largest Passenger Ferry Line

The Gummy Project Announces That Its Gummies Land on North America's Largest Passenger Ferry Line

  • The Ferry line is one of the largest ferry operators in the world carrying millions of passengers and vehicles each year.
  • The Ferry line to provide high traffic opportunities on board to grow brand awareness while forming strong consumer connections.

 The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is excited to announce that its Peachy Bees and Watermelon Sharks will be rolling out on North America's largest passenger ferry line later this summer.

"Our multi-channel sales strategy is designed to build significant brand awareness and connection with our purpose-driven mandate through highly strategic partnerships, such as this one, our Flair Airlines partnership along with Bard on the Beach - all supported by a growing retail presence and online ecommerce availability," said Mr. Charlie Lamb, CEO of The Gummy Project. "Having our product available on this ferry line puts our gummies and purpose-driven mandate in front of millions of people each year allowing us to engage consumers and drive revenue growth while aligning the brand and our great tasting gummies with people in the community."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Secures Additional Repeat Order from Existing Customer Flair Airlines

The Gummy Project Secures Additional Repeat Order from Existing Customer Flair Airlines

  • The Company had previously announced its first repeat order with existing customer Bard on the Beach.
  • Partnership with Flair rapidly accelerates The Gummy Project's growth across Canada with GUMY products being featured for sale on all Flair flights.
  • As the "Better for You" gummy company, The Gummy Project, through its Flair Airlines partnership, will extend the reach and effectiveness of its purpose driven mission to support endangered keystone species.

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is excited to announce that the Company has received a repeat order from its existing customer Flair Airlines ("Flair").

"We are very pleased to receive our second repeat order from an existing customer. We view this as another vote of confidence that our customers are very much enjoying our gummies and strongly embracing our mandate to support endangered keystone species," said Charlie Lamb, President & CEO of The Company. "We look forward to building upon the momentum that the Company has created as we continue to accelerate revenue generation and brand awareness."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Secures First Repeat Order from Existing Customer Bard on the Beach

The Gummy Project Secures First Repeat Order from Existing Customer Bard on the Beach

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is excited to announce that the Company has received its first repeat order from its existing customer Bard on The Beach ("Bard").

"We're thrilled to receive our first repeat order for our Watermelon Sharks and Peachy Bees from the local community jewel that is Bard. We view this as an indication that the local community strongly embraces our mandate to support endangered keystone species and very much enjoys our delicious gummies," said Charlie Lamb, President and CEO of GUMY.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Canadian Securities Exchange Reports June 2022 Performance Figures

Canadian Securities Exchange Reports June 2022 Performance Figures

CSE leads domestic exchanges with 16 IPOs during first half 2022

The Canadian Securities Exchange ("CSE" or "the Exchange") today announced its market statistics for the month of June 2022.

June 2022 Operating Statistics

  • Trading volume of CSE-listed securities totaled 1.2 billion shares;
  • Trading value of CSE-listed securities was $539 million;
  • CSE issuers completed 62 financings that raised an aggregate $169 million; and
  • The CSE welcomed listings from 15 new companies, including one fundamental change of an existing issuer, bringing total listed securities to 794 as at June 30, 2022.

"The Canadian Securities Exchange maintained its leading position in Canadian initial public offerings in the first half of 2022," said Richard Carleton, CSE Chief Executive Officer. "We had 16 companies go public via IPO on our exchange. That accounted for more than half of all IPOs completed on Canadian exchanges during this period, according to CPE Analytics.[1] We are delighted that entrepreneurs from around the world continue to recognize the significant benefits of a CSE listing."

What's On at the CSE

Tech Tuesdays recently wrapped up the first half of its second season. The 19 episodes featured interviews with executives from cutting-edge technology companies involved in diverse industries such as telehealth, data security, medical devices, mining, AgTech and much more. The episodes can be viewed on CSE TV, the Exchange's YouTube channel. Tech Tuesdays will return in the fall for the second half of Season 2, so the summer is a great time to catch up on any episodes of interest!

The CSE is pleased to be sponsoring and participating in the 27th annual Canadian Security Traders Association (CSTA) Conference, taking place in Niagara-on-the-Lake, Ontario on August 18-21. Conference panelists will tackle issues including diversity in investing, trading digital assets, regulation, and fintech innovations. Further information, including registration details and a preliminary conference agenda, is available here.

New Listings in June 2022

Yellow Stem Tech Inc. (YY)
G2 Energy Corp. (GTOO)
The Gummy Project Inc. (GUMY)
Avila Energy Corporation (VIK) - Fundamental Change
Arctic Fox Minerals Corp. (FOXY)
Tana Resources Corp. (TANA)
Li-FT Power Ltd. (LIFT)
Terra Balcanica Resources Corp. (TERA)
Great Republic Mining Corp. (GRM)
X1 Esports and Entertainment Ltd. (XONE)
Carmanah Minerals Corp. (CARM)
Copper Ridge Exploration Inc. (COP)
Clear Sky Lithium Corp. (POWR)
Origin Therapeutics Holdings Inc. (ORIG)
Miza II Resources Inc. (MIA)

About the Canadian Securities Exchange:

The Canadian Securities Exchange is a rapidly growing stock exchange focused on working with entrepreneurs to access the public capital markets in Canada and internationally. The Exchange's efficient operating model, advanced technology and low fee structure help companies of all sizes minimize their cost of capital and maximize access to liquidity.

The CSE offers investors in Canada and abroad access to a multi-sector collection of growth companies through a liquid, reliable and highly regulated trading platform. The Exchange is dedicated to entrepreneurship and has established itself as a leading hub for discourse in the entrepreneurial community.

STAY CONNECTED WITH THE CSE
=============================
CSE TV on YouTube: https://www.youtube.com/csetv
Instagram: https://www.instagram.com/canadianexchange/
Linkedin: https://ca.linkedin.com/company/canadian-securities-exchange
Facebook: https://www.facebook.com/CanadianSecuritiesExchange/
Twitter: https://twitter.com/CSE_News
Blog: https://blog.thecse.com/
Website: https://thecse.com/

Contact:
Richard Carleton, CEO
416-367-7360
richard.carleton@thecse.com

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics

Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) ("Turning Point") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), and the receipt of merger control clearance from the Federal Cartel Office of Germany ("FCO"), in connection with the previously announced offer (the "Offer") to acquire all outstanding shares of common stock of Turning Point at a price of $76.00 per share in an all-cash transaction for total consideration of approximately $4.1 billion. The expiration of the HSR Act waiting period occurred at 11:59 p.m. Eastern Time on August 15, 2022, and the FCO clearance was received on August 15, 2022. The Offer expired at 5:00 p.m. Eastern Time on August 15, 2022 (the "Expiration Time"), and the Offer was not extended.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220816005404/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Gilead to Acquire Remaining Worldwide Rights of Trodelvy®

Gilead will Assume Responsibility for Clinical Development and Commercialization in Greater China and South Korea, among Other Asian Markets –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for Trodelvy ® (sacituzumab govitecan) in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study

Trodelvy is the First TROP-2 Directed ADC to Show a Significant Improvement in Overall Survival in HR+HER2- Breast Cancer –

Planned Second Interim Analysis Demonstrated a Statistically Significant and Clinically Meaningful Benefit for Overall Survival

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
bowl with healthy food on it alongside an avocado and cutlery

Hungry for Change: Investing in the Plant-based Food Industry

Animal agriculture is one of the top five sources of greenhouse gas emissions, much of which is directly attributable to livestock. It's been estimated by the United Nations, for instance, that the livestock sector represents approximately 14.5 percent of all global greenhouse gas emissions. Given the current international push for sustainability, this is a problem — and people are demanding a solution.

Driven by concerns about health, climate change and animal welfare, consumers are demandingethical and sustainable alternatives to meat, dairy, fish, and poultry. Nearly two-thirds (63 percent) of respondents to a survey on flexitarian diets would swap to plant-based alternatives because they're more ethical.

Unsurprisingly, this demand represents a considerable opportunity for anyone interested in sustainable investing. According to Bloomberg Intelligence, the global plant-based food market is expected to reach a total value of US$162 billion by 2030. A survey from the Food Institute shows that 79 percent of Americans from Generation Z choose meatless options at least once or twice a week.

Keep reading...Show less

BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights

- Completed positive End-of-Phase 2 meeting with the Food and Drug Administration ("FDA") and received scientific advice from the European Medicines Agency ("EMA") to support design of its CALM Phase 3 program, which is expected to initiate in Q4 2022 -

- Ended second quarter 2022 with approximately US$384.6 million in pro-forma cash, cash equivalents and short-term investments, including net proceeds from the July 2022 financing; Cash runway extended to 2H 2025 and through the topline results of both CALM-1 and CALM-2 trials -

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma

Abecma is the first BCMA-directed CAR T cell therapy to demonstrate superiority versus standard regimens in relapsed and refractory multiple myeloma

Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced positive topline results from KarMMa-3, a Phase 3, global, randomized, multicenter, open-label study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory after two to four prior lines of therapy and refractory to the last regimen. KarMMa-3 is the first randomized clinical trial to evaluate a CAR T cell therapy in multiple myeloma. Results of a pre-specified interim analysis conducted through an independent review committee showed that KarMMa-3 met its primary endpoint of demonstrating a statistically significant improvement in progression-free survival. Treatment with Abecma also showed an improvement in the key secondary endpoint of overall response rate compared to standard regimens. Follow-up for overall survival, a key secondary endpoint, remains ongoing.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×